When we invest, we’re invested.

Menlo Raises $1.35 Billion to Fund a New Generation of Startups

This new capital will be invested by Menlo XVI, Menlo Inflection III, and their affiliated funds, in promising technology companies leading the AI transformation.

2023: The State of Generative AI in the Enterprise

We surveyed more than 450 enterprise executives across the U.S. and Europe and spoke to a dozen more to provide a view into generative AI adoption in the enterprise today.

Read the report

Building a business is a team sport. As investors, we don’t just sit on the sidelines but do whatever it takes to help our teams win.

About Us

The founders we back don’t limit themselves to what is, but relentlessly pursue what could be. We invest in transformative technology companies that are changing the way we live and work.

Portfolio

Menlo Labs starts companies. We work shoulder-to-shoulder alongside visionary founders to help groundbreaking ideas break ground.

Menlo Labs

When we’re in, we’re ALL IN. From our partners to our Fuel team, we are deeply committed to our companies as they navigate every stage of growth.

Team

There’s more to explore

Our Stories

Menlo’s Investment in OfferFit: Building the ML-Powered, Automated Experimentation Platform Marketers Need

We’re thrilled to lead OfferFit’s Series B and believe it delivers a category-disrupting solution at a time when the marketing world is looking to embrace AI.

→

Cracking the Black Box of Alts Investing: Our Series A Investment in Arch

→

Empowering Behavioral Health Providers With AI: Our Investment in Eleos

→

Partnership
is our
purpose.

A Masterclass in Scaling Developer-First Products With Industry Veteran Eeke de Milliano

Developers have become increasingly powerful decision makers and influencers within organizations, with purchasing powers of their own and dedicated budgets—particularly in light of the explosive growth of GenAI.

→

Our Investment in Vilya: AI-Enabled Development of a New Class of Medicines

Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.

→